Optimal Subcutaneous Lecanemab Dose Found in Modeling Study
The optimal dose of under-the-skin (subcutaneous) lecanemab, Eisai’s experimental therapy for early Alzheimer’s disease, has been determined in a modeling study. The dose is currently being evaluated in the Phase 3 Clarity AD open-label extension study (NCT03887455). “Eisai’s broad clinical program for lecanemab continues to deliver data…